Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-attenuated IST and Hetrombopag in elderly severe aplastic anemia
NCT07010237Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hetrombopag in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Feb 2025; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT07010237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010237.